Orchid Pharma
Drug Manufacturers - Specialty & Generic · ORCHPHARMA
Small CapHealthcareDistressed / Turnaround
Manish Dhanuka
Managing Director · Transformational
Company DNA
Innovation-Led
About
Orchid Pharma is a Small Cap company in the Healthcare sector, listed on NSE as ORCHPHARMA. With a market cap of ₹3K Cr and revenue of ₹914 Cr, it is currently in the Distressed / Turnaround phase. Known for its Innovation-Led culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. Post-restructuring, the firm is heavily focused on R&D-centric pharma recovery, necessitating a move toward scientific experimentation and product-focused development. Its strategic mandate: Requires radical operational realignment and debt management to regain profitability following significant past volatility.
FAQ
What kind of company is Orchid Pharma?
Orchid Pharma is a Small Cap Healthcare company (ORCHPHARMA) in the Distressed / Turnaround phase with a market cap of ₹3K Cr. It is classified as Innovation-Led in culture.
What is Orchid Pharma's culture and work environment like?
Orchid Pharma has a Innovation-Led culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Post-restructuring, the firm is heavily focused on R&D-centric pharma recovery, necessitating a move toward scientific experimentation and product-focused development.
Who leads Orchid Pharma?
Orchid Pharma is led by Manish Dhanuka (Managing Director), a Transformational leader with 10 years of experience.
What are Orchid Pharma's financials?
Orchid Pharma reported revenue of ₹914 Cr in FY25 with a 5-year revenue CAGR of 17.8%. Operating margin: 10.6%. Market cap: ₹3K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandTechnical-Expert
LifecycleDistressed / Turnaround
Post-restructuring, the firm is heavily focused on R&D-centric pharma recovery, necessitating a move toward scientific experimentation and product-focused development.
Mandate
Requires radical operational realignment and debt management to regain profitability following significant past volatility.
Requires radical operational realignment and debt management to regain profitability following significant past volatility.
Financials
Revenue FY25₹914 Cr
PAT FY25₹100 Cr
Rev CAGR 5Y17.8%
OPM10.6%
NPM10.9%
ROE7.9%
ROCE6.9%
P/E136.9
Fwd P/E18.8
P/B2
D/E22.1
Mkt Cap₹3K Cr
Promoter69.8%
Institutional17.1%
Similar Culture
Could You Lead Orchid Pharma?
Take the Genome Benchmark →